Clinical Prognostic Factors and Integrated Multi-Omics Studies Identify Potential Novel Therapeutic Targets for Pediatric Desmoid Tumor

[1]  Jihwan Park,et al.  Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy , 2022, Military Medical Research.

[2]  Wenyu Lin,et al.  Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3SPOP E3 ligase in cancer cells , 2022, Nature Communications.

[3]  Zhihui Feng,et al.  Hepatic Suppression of Mitochondrial Complex II Assembly Drives Systemic Metabolic Benefits , 2022, Advanced science.

[4]  Robin L. Jones,et al.  The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling , 2021, Frontiers in Cell and Developmental Biology.

[5]  M. Tiirikainen,et al.  Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers , 2020, Hepatoma research.

[6]  P. Dileo,et al.  Successful implementation of an international desmoid tumor virtual tumor board: A novel platform for the management of rare tumors , 2020, Rare tumors.

[7]  Zi-Qing Li,et al.  CRISPR/Cas9 from bench to bedside: what clinicians need to know before application? , 2020, Military Medical Research.

[8]  R. Ruch.  Gap Junctions and Connexins in Cancer Formation, Progression, and Therapy , 2020, Cancers.

[9]  A. Minelli,et al.  Recent Advances in Desmoid Tumor Therapy , 2020, Cancers.

[10]  Philip S. Yu,et al.  β-catenin S45F mutation results in apoptotic resistance , 2020, Oncogene.

[11]  H. Gevensleben,et al.  Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis – A systematic analysis of 204 cases , 2020, Scientific Reports.

[12]  Robin L. Jones,et al.  The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.

[13]  B. Ning,et al.  Clinical prognostic factors for pediatric extra-abdominal desmoid tumor: analyses of 66 patients at a single institution , 2018, World Journal of Surgical Oncology.

[14]  David M. Thomas,et al.  Locally Aggressive Connective Tissue Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Baur-Melnyk,et al.  Desmoid Tumours of the extremity and trunk. A retrospective study of 44 patients , 2018, BMC Musculoskeletal Disorders.

[16]  B. Alman,et al.  A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates , 2018, Scientific Reports.

[17]  C. Creighton,et al.  Targeting the notch pathway: A potential therapeutic approach for desmoid tumors , 2015, Cancer.

[18]  J. Blay,et al.  Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival , 2015, Clinical Cancer Research.

[19]  Andrew,et al.  β-Catenin mutation status and outcomes in sporadic desmoid tumors. , 2013, The oncologist.

[20]  J. Coindre,et al.  CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics , 2012, Modern Pathology.

[21]  Lian Chen,et al.  Analysis of β-Catenin Expression and Exon 3 Mutations in Pediatric Sporadic Aggressive Fibromatosis , 2012, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[22]  P. Cin,et al.  Autopsy , 2011, Laboratory Investigation.

[23]  Jianguo Xia,et al.  Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst , 2011, Nature Protocols.

[24]  P. Hohenberger,et al.  Desmoid tumors: clinical features and treatment options for advanced disease. , 2011, The oncologist.

[25]  A. Lazar,et al.  Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. , 2008, The American journal of pathology.

[26]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..